Imagion Biosystems Ltd. AI Stock Analysis
Want to see AU:IBX full AI Analyst Report?
Imagion Biosystems Ltd. (IBX) AI Stock Analysis
Imagion Biosystems Ltd.
(ASX:IBX)
AU:IBX receives the minimum score due to an extremely precarious financial position, characterized by zero revenue, technical insolvency, and severe unprofitability. A complete lack of technical momentum and a highly negative valuation profile further emphasize immediate solvency risks, rendering the company heavily reliant on external capital to survive.
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 2.97M
- Dividend Yield
- ―
- Average Volume (3M)
- 893.08K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 1.74
- Revenue Growth
- -100.00%
- EPS Growth
- -3.67%
- Country
- Australia
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Imagion Biosystems Ltd. Business Overview & Revenue Model
Company Description
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic reso...
Imagion Biosystems Ltd. Financial Statement Overview
Summary
Financial performance reflects severe distress with zero recent revenue, negative stockholders' equity, and persistent cash burn, raising immediate solvency risks.
Income Statement
8Very NegativeBalance Sheet
5Very NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 2.67M | 1.08M | 473.43K | 232.87K |
| Gross Profit | -6,369 | -8,808 | 2.26M | -279.83K | -3.14M | -2.47M |
| EBITDA | -4.67M | -3.58M | -355.52K | -10.30M | -11.03M | -5.62M |
| Net Income | -4.63M | -4.31M | -2.07M | -12.47M | -9.81M | -6.02M |
Balance Sheet | ||||||
| Total Assets | 671.92K | 2.04M | 2.80M | 4.59M | 9.98M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 32.46K | 1.85M | 2.67M | 227.08K | 4.45M | 13.39M |
| Total Debt | 2.19M | 2.56M | 2.85M | 6.04M | 4.60M | 46.02K |
| Total Liabilities | 4.09M | 4.21M | 5.09M | 8.37M | 5.30M | 809.88K |
| Stockholders Equity | -3.42M | -2.16M | -2.28M | -3.79M | 4.68M | 13.31M |
Cash Flow | ||||||
| Free Cash Flow | -4.05M | -4.04M | -1.27M | -8.51M | -9.21M | -5.29M |
| Operating Cash Flow | -4.05M | -4.04M | -1.27M | -8.32M | -8.70M | -5.07M |
| Investing Cash Flow | 0 | 0 | 83.74K | -190.38K | -468.73K | -310.09K |
| Financing Cash Flow | 3.23M | 3.24M | 3.61M | 4.29M | -962.06K | 5.15M |
Imagion Biosystems Ltd. Peers Comparison
Overall Rating
AU:IDX48Neutral
AU:BDX42Neutral
AU:GSS38Underperform
AU:RHY38Underperform
AU:IBX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | AUD 619.98M | 28.32 | 3.24% | 5.60% | 25.73% | 390.83% | |
| 42Neutral | AUD 22.20M | -2.98 | -881.94% | ― | 743.51% | -1.52% | |
| 38Underperform | AUD 16.35M | -1.14 | -35.10% | ― | -9.10% | 31.75% | |
| 38Underperform | AUD 21.84M | -3.39 | -205.17% | ― | 239.64% | -37.21% | |
| 37Underperform | AUD 4.02M | -0.49 | 165.88% | ― | -100.00% | -3.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:IBX | Imagion Biosystems Ltd. | 0.01 | -0.01 | -52.38% | |
| AU:BDX | BCAL Diagnostics Limited | 0.06 | -0.03 | -33.33% | |
| AU:RHY | Rhythm Biosciences Ltd. | 0.06 | -0.04 | -36.84% | |
| AU:GSS | Genetic Signatures Ltd. | 0.07 | -0.21 | -74.55% | |
| AU:IDX | Integral Diagnostics Ltd. | 1.69 | -0.77 | -31.50% |
Imagion Biosystems Ltd. Corporate Events
Imagion Executes First U.S. Site Agreement for MagSense HER2+ Breast Cancer Trial
Imagion Biosystems has executed a Clinical Trial Agreement with oncology-focused Regis Clinical Research, its first contracted site for the MagSense HER2 Imaging Agent Phase 1b/2 trial in HER2+ breast cancer. The agreement enables progress toward sit...
Imagion Biosystems Issues Shares for Corporate Advisory Services
Imagion Biosystems is a clinical-stage medical imaging company developing MagSense®, a non-radioactive magnetic nanoparticle MRI agent designed to support earlier and more precise cancer detection. Its applications target HER2-positive breast, prosta...
Imagion Biosystems Issues Shares for Advisory Fees
Imagion Biosystems Limited reported the issue of 2,393,144 fully paid ordinary shares on November 6, 2026, in lieu of fees for corporate advisory services.The newly issued shares were applied for quotation on the Australian Securities Exchange under...
Imagion Biosystems Reshapes Board Roles as It Advances Cancer Imaging Programs
Imagion Biosystems has announced the resignation of Non-Executive Director and Company Secretary Melanie Leydin, effective 30 October 2026, coinciding with her retirement and a shift in focus to other commitments. Leydin, who joined the board in Augu...
Imagion Biosystems Corrects Convertible Note Balance in Amended Quarterly Cash Report
Imagion Biosystems has lodged an amended Appendix 4C for the quarter ended 30 September 2026 to correct the reported balance of its financing facilities. The revision updates the value of outstanding convertible notes under a $15 million facility wit...
Imagion Biosystems Advances U.S. MagSense HER2 Trial and Restores Nanoparticle Manufacturing
Imagion Biosystems reported substantial progress in preparing its Phase 1b/2 MagSense® HER2 breast cancer clinical trial in the U.S., moving towards first patient enrolment. The company has finalized key study materials, completed manufacturing and s...
Imagion Wins Central Ethics Approval for Phase 2 MagSense Cancer Trial
Imagion Biosystems has secured central Institutional Review Board ethics approval from Advarra for its Phase 1b/2 trial of the MagSense® HER2 imaging agent in HER2-positive breast cancer. This clearance, combined with prior FDA IND approval, meets ke...
Imagion Biosystems Restores MagSense Nanoparticle Manufacturing via nanoComposix Deal
Imagion Biosystems has signed a Master Service Agreement with nanoComposix, a specialty nanoparticle CDMO, to resume pharmaceutical-grade manufacturing of its MagSense® nanoparticles in alignment with U.S. FDA product quality standards. By outsourcin...
Imagion Biosystems promotes molecular MRI platform for early cancer detection
Imagion Biosystems has released an investor presentation outlining its molecular MRI platform as a next-generation imaging technology for early cancer detection. The company positions this approach as a breakthrough in oncology imaging, aiming to enh...
Imagion Biosystems issues cleansing notice on new options
Imagion Biosystems has issued a cleansing notice following the allotment of 40,208,334 listed options expiring on 13 December 2027, including options granted to participants in a recent placement and to the lead manager. The options were issued witho...
Imagion Biosystems Seeks ASX Quotation for 7.5 Million New Options
Imagion Biosystems Limited has applied to the ASX for quotation of new options, designated under the security code IBXO, further integrating these instruments into its listed securities structure. The options relate to securities issued to the lead m...
Imagion Biosystems Seeks ASX Quotation for 32.7 Million Options
Imagion Biosystems has applied to the ASX for quotation of new options under the code IBXO, expanding its listed securities on the market. The company is seeking quotation for a total of 32,708,334 options expiring on 13 December 2027, issued across...
Imagion Biosystems Options Lapse, Streamlining Capital Structure
Imagion Biosystems has announced the expiry and cessation of 1,164,597 listed options with the ASX code IBXAAU, which carried an exercise price of $0.90 and an expiry date of August 25, 2026. The options lapsed without being exercised, resulting in a...
Imagion Biosystems Details Director’s Milestone-Linked Equity Holdings
Imagion Biosystems has disclosed a change in Director Robert Romeo Proulx’s interests in the company’s securities, detailing his holdings of ordinary shares, listed and unlisted options, and multiple classes of performance rights tied to clinical and...
Imagion Biosystems Half-Year Loss Widens as Auditors Flag Going-Concern Risk
Imagion Biosystems reported a half-year loss after tax of $1.98 million for the period ended 30 June 2026, a 19.2% increase on the prior corresponding period, with no dividends declared or paid. Net tangible assets per share fell to negative 0.63 cen...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 26, 2026
